ID: ALA4059630

Max Phase: Preclinical

Molecular Formula: C27H39FN4O2

Molecular Weight: 470.63

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1cc(-c2nc(CN3CCC(C(=O)NCCCN4C[C@H](C)C[C@H](C)C4)CC3)co2)ccc1F

Standard InChI:  InChI=1S/C27H39FN4O2/c1-19-13-20(2)16-32(15-19)10-4-9-29-26(33)22-7-11-31(12-8-22)17-24-18-34-27(30-24)23-5-6-25(28)21(3)14-23/h5-6,14,18-20,22H,4,7-13,15-17H2,1-3H3,(H,29,33)/t19-,20+

Standard InChI Key:  GUCPCTHHCYQSTE-BGYRXZFFSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 470.63

Molecular Weight (Monoisotopic): 470.3057

AlogP: 4.49

#Rotatable Bonds: 8

Polar Surface Area: 61.61

Molecular Species: BASE

HBA: 5

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 9.81

CX LogP: 3.77

CX LogD: 1.16

Aromatic Rings: 2

Heavy Atoms: 34

QED Weighted: 0.58

Np Likeness Score: -1.89

References

1. He S, Li K, Lin B, Hu Z, Xiao J, Hu X, Wang AQ, Xu X, Ferrer M, Southall N, Zheng W, Aubé J, Schoenen FJ, Marugan JJ, Liang TJ, Frankowski KJ..  (2017)  Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle.,  60  (14): [PMID:28636348] [10.1021/acs.jmedchem.7b00561]

Source

Source(1):

• Scientific Literature